Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)
Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock
Sponsor: B. Braun Melsungen AG
Listed as NCT00135473, this PHASE3 trial focuses on Septic Shock and Severe Sepsis and remains completed. Sponsored by B. Braun Melsungen AG, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- B. Braun Melsungen AG
- German Federal Ministry of Education and Research
- HemoCue
- Novo Nordisk A/S
- SepNet - Critical Care Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Augsburg, Germany , Berlin, Germany , Brandenburg, Germany , Dresden, Germany , Erfurt, Germany , Erlangen, Germany , Greifswald, Germany , Göttingen, Germany , Halle, Germany and 4 more locations